Press releases

Company supports efforts of International Diabetes Federation to promote worldwide diabetes care and prevention

"We are very pleased with the decision by the Canadian Federal Court dismissing this case," said Boston Scientific's Chief Operating Officer.

ALTRUA™ is Company's most advanced pacemaker and delivers enhanced therapies while maintaining its small size and battery longevity.

Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval and market launch of its ALTRUA™ family of pacemakers. ALTRUA is Boston...

Ruling from World Intellectual Property Organization (WIPO) arbitration panel finds no infringement

A live webcast and replay of the May 6 conference session will be available

A live webcast and replay of the April 30 session will be available.

MADIT-CRT trial designed to test whether CRT-Ds can slow the progression of heart failure in heart attack survivors

Award recognizes Boston Scientific's successful use of electronic transactions to improve supply chain efficiency for customers and suppliers

"We continued to make good progress during the quarter, particularly in our efforts to bring expenses in line with revenues," said CEO Jim Tobin.

Company plans to launch product immediately

Acquisition follows a 2007 development agreement to pursue therapeutic solutions for atrial fibrillation, or "Afib"

Emerging technology will potentially enable access to MRI exams for implantable cardiac device patients

ACUITY® Steerable lead also receives reimbursement approval; Company plans to launch product immediately

A live webcast and replay of the April 22 conference call will be available.

Nationally known attorney specializing in medical device and pharmaceutical litigation; will serve on the Company's Executive Committee

Judgment entered in favor of Guidant and its former directors/officers

Data was presented at SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago

Results from TAXUS IV and V randomized clinical trials favor DES compared to bare-metal stents

At two years, Company's TAXUS® and PROMUS™ Stents demonstrate positive and similar outcomes

Sale is the latest example of Company's commitment to realigning its cost structure; overall goal is to strengthen Boston Scientific for the future

Two-year outcomes confirm the favorable results seen in previous clinical trials

One-year pooled ARRIVE data showed similarly low rates of stent-related cardiac death, myocardial infarction, stent thrombosis, and major cardiac events across the two patient subsets

Presentations to include clinical data for the TAXUS® paclitaxel-eluting coronary stent in a variety of high-risk patient populations

A live webcast and replay of the March 18 session will be available. Learn how to tune in